Back to search
FDAFDA · Food and drugs·Recall number Z-0733-2024

VACUETTE TUBE 4 ml FX Sodium Fluoride/Potassium Oxalate, Item #454297, 13x75 grey cap-black ring, non-ridged.

Published January 24, 2024 · Recall initiated: December 12, 2023

Summary

FDA records medical device Class II recall Z-0733-2024, published January 24, 2024 and initiated December 12, 2023. Recalling firm: Greiner Bio-One North America, Inc.; Status: Ongoing; Reported quantity: 495,600 tubes; Lot: Lot #A221135N, Exp. date 03/02/2024, UDI-DI Case label 39120017575130, UDI Rack label 29120017575133. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Tubes have missing additive/anticoagulant resulting in clotting in most cases. A completely clotted sample would lead to no results being reported, which could lead to a delay in treatment or diagnosis. An erroneous glucose or lactose result from a partially clotted sample could lead to inappropriate treatment.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Greiner Bio-One North America, Inc.
Distributor
US Nationwide distribution in the states of CT, FL, IA, IL, MO, NC, NY, PA, TN, and VA.
Lot
Lot #A221135N, Exp. date 03/02/2024, UDI-DI Case label 39120017575130, UDI Rack label 29120017575133.
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was VACUETTE TUBE 4 ml FX Sodium Fluoride/Potassium Oxalate, Item #454297, 13x75 grey cap-black ring, non-ridged. recalled?

Yes. FDA published recall Z-0733-2024 on January 24, 2024. Reported hazard: Tubes have missing additive/anticoagulant resulting in clotting in most cases. A completely clotted sample would lead to no results being reported, which could lead to a delay in treatment or diagnosis. An erroneous glucose or lactose result from a partially clotted sample could lead to inappropriate treatment.

What should I do if I have this product?

Voluntary: Firm initiated · Letter